Pathophysiology of inflammatory and autoimmune myopathies

Presse Medicale

Volumn 40, Issue 4, 2011, Pages

  Dalakas, Marinos C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMYLOID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; PREDNISONE; RITUXIMAB;

ALZHEIMER DISEASE; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CAUSAL ATTRIBUTION; CD8+ T LYMPHOCYTE; CELL STRESS; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; MEDIATOR RELEASE; MICROANGIOPATHY; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; POLYMYOSITIS; PROTEIN FOLDING; SHORT SURVEY; VIRUS INFECTION;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; HUMANS; IMMUNOMODULATION; INFLAMMATION MEDIATORS; MUSCLES; MYOSITIS; MYOSITIS, INCLUSION BODY; NECROSIS; POLYMYOSITIS; PROTEOSTASIS DEFICIENCIES; TREATMENT OUTCOME;

EID: 79953768705     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.01.005     Document Type: Short Survey

References (112)

1. Dalakas M.C. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010, 10:346-352.
2. Schmidt J., Dalakas MC Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Exp Opin 2010, 4:241-250.
3. Dalakas MC. An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2010, doi:10.1111/j.1365-2990.2010.01153.x.
4. Dalakas M.C. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
5. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
6. Engel A.G., Hohlfeld R., Banker B.Q. The polymyositis and dermatomyositis syndrome. Myology 2008, 1335-1383. McGraw-Hill, New York. A.G. Engel, C. Franzini-Armstrong (Eds.).
7. Dalakas M.C., Karpati G. The inflammatory myopathies. Disorders of voluntary muscle (8th Edition) 2010, 427-452. Cambridge University Press, Cambridge, UK. G. Karpati, D. Hilton-Jones, K. Bushby, R.C. Griggs (Eds.).
8. Askanas V., Engel W.K., Nogalska A. Inclusion-body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009, 19:493-506.
9. Needham M., Mastaglia F.L. Sporadic inclusion-body myositis: a continuing puzzle. Neuromuscul Disord 2008, 18:6-16.
10. Dalakas M.C. Sporadic inclusion-body myositis: diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006, 2:437-447.
11. Dalakas M.C. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006, 4:219-227.
12. Kissel J.T., Mendell J.R., Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:329.
13. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343-356.
14. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994, 94:1729-1735.
15. Dalakas M.C. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995, 37:74-86.
16. Lundberg I., Brengman J.M., Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies. Duchenne's dystrophy and non-weak controls. J Neuroimmunol 1995, 63:9-16.
17. Tews D.S., Goebel H.H. Cytokine expression profiles in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996, 55:342-347.
18. Confalonieri P., Bernasconi P., Megna P., Galbiati S., Cornelio F., Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000, 59:164-169.
19. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., Schröder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 2002, 58:1779-1785.
20. Figarella-Branger D., Civate M., Bartoli C., Pellissier J.F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003, 28:659-682.
21. Mammen A.L., Casciola-Rosen L.A., Hall J.C., Christopher-Stine L., Corse A.M., Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009, 60:3784-3793.
22. Gallardo E., de Andrés I., Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 2001, 60:847-855.
23. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
24. Walsh R.J., Kong S.W., Yao Y., Jallal B., Kiener P.A., Pinkus J.L., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784-3792.
25. Tezak Z., Hoffman E.P., Lutz J.L., Fedczyna T.O., Stephan D., Bremer E.G., et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154-4163.
26. Raju R., Dalakas M.C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005, 128:1887-1896.
27. Amemiya K., Semino-Mora C., Granger R.P., Dalakas M.C. Downregulation of TGF-(1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000, 94:99-104.
28. Leff R.L., Love L.A., Miller F.W., Greenberg S.J., Klein E.A., Dalakas M.C., et al. Viruses in the idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992, 339:1192-1195.
29. Leon-Monzon M., Dalakas M.C. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. Ann Neurol 1992, 32:219-222.
30. Hohlfeld R., Engel A.G. The immunobiology of muscle. Immunol Today 1994, 15:269-274.
31. Wiendl H., Hohlfeld R., Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005, 26:373-380.
32. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibres invaded by T cells. Ann Neurol 1984, 16:193-208.
33. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988, 23:168-173.
34. Engel A.G., Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209-215.
35. Engel A.G., Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:702-721.
36. Goebels N., Michaelis D., Engelhardt M., Huber S., Bender A., Pongratz D., et al. Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis. J Clin Invest 1996, 97:2905.
37. Schmidt J., Rakocevic G., Raju R., Dalakas M.C. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 2004, 127:1182-1190.
38. Hohlfeld R., Engel A.G. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991, 29:498-507.
39. Behrens L., Bender A., Johnson M.A., Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997, 120:929.
40. Schneider C., Gold R., Dalakas M.C., Schmied M., Lassmann H., Toyka K.V., et al. MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: Studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 1996, 55:1205-1209.
41. Pruitt J.N., Showalter C.J., Engel A.G. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996, 39:139-143.
42. Karpati G., Pouliot Y., Carpenter S. Expression of immunoreactive major histocompatability complex products in human skeletal muscles. Ann Neurol 1988, 23:64-72.
43. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunologicalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989, 20:224-231.
44. Mantegazza R., Hughes S.M., MitchellD, Travis M., Blau H.M., Steinman L. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 1991, 41:1128.
45. Bao S.S., King N.J., dos Remedios C.G. Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon. Immunol Cell Biol 1990, 68:235-241.
46. Hohlfeld R., Engel A.G. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol 1990, 136:503.
47. De Bleecker J.L., Meire V.I., Declercq W., Van Aken H.E. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999, 9:239.
48. Raju R., Vasconcelos O., Granger R., Dalakas M.C. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003, 141:125-131.
49. Confalonieri P., Oliva L., Andreetta F., Lorenzoni R., Dassi P., Mariani E., et al. Muscle inflammation and MHC class I upregulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003, 142:130-136.
50. Bender A., Ernst N., Iglesias A., Dornmair K., Wekerle H., Hohlfeld R. T cell receptor in polymyositis: clonal expansion of autoaggressive CD81 T cells. J Exp Med 1995, 181:1863-1868.
51. Mantegazza R., Andreetta F., Bernasconi P., Baggi F., Oksenberg J.R., Simoncini O., et al. Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis. J Clin Invest 1993, 91:2880-2886.
52. O'Hanlon T.P., Dalakas M.C., Plotz P.H., Miller F.W. Predominant TCR-alpha-beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994, 152:2569-2576.
53. Benveniste O., Herson S., Salomon B., Dimitri D., Trébeden-Nègre H., Jean L., et al. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol 2004, 56:867-872.
54. Hofbauer M., Wiesener S., Babbe H., Roers A., Wekerle H., Dornmair K., et al. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci U S A 2003, 100:4090-4095.
55. Fyhr I.M., Moslemi A.R., Mosavi A.A., Lindberg C., Tarkowski A., Oldfors A. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 1997, 79:185-189.
56. Bender A., Behrens L., Engel A.G., Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 1998, 84:86-91.
57. Nishio J., Suzuki M., Miyasaka N., Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001, 167:4051-4058.
58. Amemiya K., Granger R.P., Dalakas M.C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000, 123:2030-2039.
59. Hohlfeld R., Engel A.G., Kunio L.I., Harper M.C. Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. N Engl J Med 1991, 324:877-881.
60. Puschke G., Ruegg D., Hohlfeld R., Engel A.G. Autoaggressive myocytotoxic T-lymphocytes expressing an unusual gamma delta T cell receptor. J Exp Med 1992, 176:1785-1789.
61. Wiendl H., Malotka J., Holzwarth B., Weltzien H.U., Wekerle H., Hohlfeld R., et al. An autoreactive gamma delta TCR derived from a polymyositis lesion. J Immunol 2002, 169:515-521.
62. Wiendl H., Mitsdoerffer M., Schneider D., Melms A., Lochmuller H., Hohlfeld R., et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule. ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003, 126:1026-1035.
63. Murata K., Dalakas M.C. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am J Pathol 1999, 155:453-460.
64. Choi Y.C., Dalakas M.C. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000, 54:65-71.
65. De Bleecker J.L., Engel A.G. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994, 53:369-376.
66. Schmidt J., Barthel K., Wrede A., Salajegheh M., Bähr M., Dalakas MC Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-4050.
67. Greenberg S.A., Pinkus G.S., Amato A.A., Pinkus J.L. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007, 35:17-23.
68. Bradshaw E.M., Orihuela A., McArdel S.L., Salajegheh M., Amato A.A., Hafler D.A., et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007, 178:547-556.
69. Miller T., Al-Lozi M.T., Lopate G., Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002, 73:420-428.
70. Hengstman G.J., van Engelen B.G., van Venrooij W.J. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004, 6:692-699.
71. Christofer-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200 and 100kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
72. Dalakas M.C. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009, 80:832-838.
73. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia FL Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007, 17:194-200.
74. Askanas V., Engel W.K., Alvarez R.B. Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 1993, 43:1265-1267.
75. Chahin N., Engel A.G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008, 70:418-424.
76. Nogalska A., Terracciano C., D'Agostino C., King Engel W., Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009, 118:407-413.
77. Goldfarb L.G., Dalakas M.C. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest 2009, 119:1806-1813.
78. Eisenberg I., Avidan N., Potikha T., Hochner H., Chen M., Olender T., et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001, 29:83-87.
79. Dalakas M.C. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006, 66:S33-S38.
80. Dalakas M.C., Pezeshkpour G.H., Gravell M., Sever J.L. Polymyositis in patients with AIDS. JAMA 1986, 256:2381-2383.
81. Dalakas M.C., Pezeshkpour G.H. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988, 23:38-48.
82. Morgan O.S., Rodgers-Johnson P., Mora C., Char G. HTLV-1 and polymyositis in Jamaica. Lancet 1989, 12:1184-1187.
83. Illa I., Nath A., Dalakas M.C. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol 1991, 29:474-481.
84. Leon-Monzon M., Lamperth L., Dalakas M.C. Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV-polymyositis. Muscle Nerve 1993, 16:408-413.
85. Cupler E.J., Leon-Monzon M., Miller J., Semino-Mora C., Anderson T.L., Dalakas M.C. Inclusion body myositis in HIV-I and HTLV-I infected patients. Brain 1996, 19:1887-1893.
86. Saito M., Higuchi I., Saito A., Izumo S., Usuku K., Bangham C.R., et al. Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 2002, 186:1231-1241.
87. Ozden S., Cochet M., Mikol J., Teixeira A., Gessain A., Pique C. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 2004, 78:10320-10327.
88. Dalakas M.C., Rakocevic G., Shatunov A., Goldfarb L., Salajegheh M. IBM with HIV infection: 4 new cases withclonal expansion of viral-specific T cells. Ann Neurol 2007, 61:466-475.
89. Semino-Mora C., Dalakas M.C. Rimmed vacuoles with b-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 1998, 29:1128-1133.
90. Salajegheh M., Pinkus J.L., Nazareno R., Amato A.A., Parker K.C., Greenberg S.A. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009, 40:520-528.
91. De Bleecker J.L., Ertl B.B., Engel A.G. Patterns of abnormal protein expression in target formations and unstructured cores. Neuromuscul Disord 1996, 6:339-349.
92. Fidzianska A., Rowinska-Marcinska K., Hausmanowa-Petrusewicz I. Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol 2004, 104:197-203.
93. Selcen D., Ohno K., Engel A.G. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 2004, 127:439-451.
94. Ferrer I., Martin B., Castano J.G., Lucas J.J., Moreno D., Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004, 63:484-498.
95. Ferrer I., Carmona M., Blanco R., Moreno D., Torrejón-Escribano B., Olivé M. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol 2005, 15:101-108.
96. Weihl C.C., Temiz P., Miller S.E., Watts G., Smith C., Forman M., et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008, 79:1186-1189.
97. Lünemann J.D., Schmidt J., Schmid D., Barthel K., Wrede A., Dalakas M.C., et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007, 61:476-483.
98. Schmid D., Münz C. Localization and MHC class II presentation of antigens targeted for macroautophagy. Methods Mol Biol 2008, 445:213-225.
99. Dalakas M.C. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998, 55:1509-1512.
100. Dalakas M.C. Molecular links between inflamation and degeneration: Lessons on "Neuroinflammation" using IBM as a model. Ann Neurol 2008, 64:1-3.
101. Kitazawa M., Trinh D.N., La Ferla F.M. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008, 64:15-24.
102. Banwell B.L., Engel A.G. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000, 54:1020-1021.
103. Muth I.E., Barthel K., Bähr M., Dalakas M.C., Schmidt J. Pro-inflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009, 80:1344-1349.
104. Dalakas M.C. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 2006, 16:223-236.
105. Dalakas M.C. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010, 6:129-137.
106. Mastalgia F.L., Garlepp M.J., Phillips B.A., Zilko P.J. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003, 27:407-425.
107. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New Engl J Med 1993, 329:1993-2000.
108. Valiyil R., Casciola-Rosen L., Hong G., Mammen A., Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 2010, 62:1328-1334.
109. Dalakas M.C., Sekul E.A., Cupler E.J., Sivakumar K. The efficacy of high dose intravenous immunoglobulin (IVIg) in patients with inclusion-body myositis (IBM). Neurology 1997, 48:712-716.
110. Layzer R., Lee H.S., Iverson D., Margeta M. Dermatomyositis with inclusion body myositis pathology. Muscle Nerve 2009, 40:469-471.
111. Dalakas M.C., Rakocevic G., Schmidt J., Salajegheh M., McElroy B., Harris-Love M.O., et al. Effect ofAlemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009, 132:1536-1544.
112. Hughes R.A., Dalakas M.C., Cornblath D.R., Latov N., Weksler M.E., Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009, 158:34-42.